Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.
about
Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Monitoring of erlotinib in pan ...... y based pharmacokinetic model.
@en
Monitoring of erlotinib in pan ...... y based pharmacokinetic model.
@nl
type
label
Monitoring of erlotinib in pan ...... y based pharmacokinetic model.
@en
Monitoring of erlotinib in pan ...... y based pharmacokinetic model.
@nl
prefLabel
Monitoring of erlotinib in pan ...... y based pharmacokinetic model.
@en
Monitoring of erlotinib in pan ...... y based pharmacokinetic model.
@nl
P2093
P2860
P1476
Monitoring of erlotinib in pan ...... ly based pharmacokinetic model
@en
P2093
Azra Sahmanovic Hrgovcic
Christian Dittrich
Marie Kitzmueller
Nairi Kirchbaumer Baroian
Philipp Buchner
P2860
P2888
P304
P356
10.1007/S00280-018-3545-4
P577
2018-02-16T00:00:00Z
P6179
1101082788